Begins Coverage on Trinity Biotech (NASDAQ:TRIB) initiated coverage on shares of Trinity Biotech (NASDAQ:TRIBFree Report) in a report published on Monday morning. The firm issued a buy rating on the stock.

Trinity Biotech Trading Up 10.8 %

Shares of TRIB stock opened at $2.00 on Monday. Trinity Biotech has a 1 year low of $1.49 and a 1 year high of $5.50. The firm’s fifty day moving average price is $1.77 and its two-hundred day moving average price is $2.13. The firm has a market capitalization of $15.24 million, a P/E ratio of -0.72 and a beta of 1.16.

Trinity Biotech (NASDAQ:TRIBGet Free Report) last issued its earnings results on Thursday, April 4th. The company reported ($0.68) earnings per share (EPS) for the quarter. The firm had revenue of $13.43 million for the quarter. As a group, equities research analysts forecast that Trinity Biotech will post -2.17 EPS for the current fiscal year.

About Trinity Biotech

(Get Free Report)

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.

Read More

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with's FREE daily email newsletter.